Recently, a PSMA ligand with two 4-(p-iodophenyl)butyrate residues and two PSMA-binding moieties was radiolabeled with Ac-225, and evaluation showed that elevated tumor uptake and longer renal retention were inferior to the compound with one PSMA and one albumin-binding residue [145]. Here, ALB is linked to neoplasm.